[Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases]. 2024

A-L Stefanski, and T Dörner, and C Kneitz
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. ana-luisa.stefanski@charite.de.

Patients with inflammatory rheumatic diseases have a higher risk of infections in comparison to the general population. For this patient group, in addition to cardiovascular diseases, infections play an important role with respect to morbidity and mortality. Even if it is difficult to make concrete statements with respect to individual diseases, it can be assumed that there is a lower risk of infections in inflammatory joint diseases in comparison to connective tissue diseases and vasculitides. The increased risk of infections is determined by multiple factors, whereby the underlying factors are classified into three main categories: patient-related factors (age, comorbidities, lifestyle), disease-related factors (immunological dysfunction as part of the disease pathophysiology) and drug-related factors (type and dosage of the immunosuppression and/or immunomodulation). An improved understanding of the complexity of these associations enables the optimization of treatment and disease control taking the individual risk factors into account, with the aim of a significant reduction in the risk of infections.

UI MeSH Term Description Entries
D007121 Immunocompetence The ability of lymphoid cells to mount a humoral or cellular immune response when challenged by antigen. Competence, Immunologic,Immunologic Competence,Immunological Competence,Competence, Immunological
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012213 Rheumatic Fever A febrile disease occurring as a delayed sequela of infections with STREPTOCOCCUS PYOGENES. It is characterized by multiple focal inflammatory lesions of the connective tissue structures, such as the heart, blood vessels, and joints (POLYARTHRITIS) and brain, and by the presence of ASCHOFF BODIES in the myocardium and skin. Acute Rheumatic Fever,Arthritis, Rheumatic, Acute,Rheumatism, Articular, Acute,Arthritis, Acute Rheumatic,Inflammatory Rheumatism,Polyarthritis Rheumatica,Rheumatic Arthritis,Rheumatism, Acute Articular,Acute Articular Rheumatism,Acute Articular Rheumatisms,Acute Rheumatic Arthritides,Acute Rheumatic Arthritis,Acute Rheumatic Fevers,Arthritis, Rheumatic,Articular Rheumatism, Acute,Fever, Acute Rheumatic,Fever, Rheumatic,Fevers, Acute Rheumatic,Inflammatory Rheumatisms,Polyarthritis Rheumaticas,Rheumatic Arthritides,Rheumatic Arthritis, Acute,Rheumatic Fever, Acute,Rheumatic Fevers,Rheumatism, Inflammatory
D012216 Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement. Rheumatism,Disease, Rheumatic,Diseases, Rheumatic,Rheumatic Disease
D015897 Comorbidity The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.

Related Publications

A-L Stefanski, and T Dörner, and C Kneitz
January 1982, Annals of the rheumatic diseases,
A-L Stefanski, and T Dörner, and C Kneitz
October 2016, Best practice & research. Clinical rheumatology,
A-L Stefanski, and T Dörner, and C Kneitz
September 2021, Zeitschrift fur Rheumatologie,
A-L Stefanski, and T Dörner, and C Kneitz
July 2010, Zeitschrift fur Rheumatologie,
A-L Stefanski, and T Dörner, and C Kneitz
May 2021, Zeitschrift fur Rheumatologie,
A-L Stefanski, and T Dörner, and C Kneitz
February 2006, Rheumatic diseases clinics of North America,
A-L Stefanski, and T Dörner, and C Kneitz
September 1970, Die Agnes Karll-Schwester, der Krankenpfleger,
A-L Stefanski, and T Dörner, and C Kneitz
April 2009, MMW Fortschritte der Medizin,
A-L Stefanski, and T Dörner, and C Kneitz
January 1954, Acta physiotherapica et rheumatologica Belgica,
Copied contents to your clipboard!